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following a 2-week, open-label, observation period during which subjects continued 
to receive olanzapine. The rate of ATP-I Il metabolic syndrome, and the long term 
risk for diabetes and CHD was estimated and compared between arms. Brazilian costs 
and health resource estimates were applied to each event. Established risk functions 
were used to estimate diabetes and CHD risk. RESULTS: Among all patients, the 
baseline rate of metabolic syndrome was 89%. At 16 weeks, 80.3% of olanzapine 
versus 60% of aripiprazole patients exhibited metabolic syndrome (RR: 0.75; 95%Cl: 
0.61–0.92, p  0.006). Diabetes risk increased by 1.3% (aripiprazole patients) and 
6.4% (olanzapine patients), risk difference  5.1 %. CHD risk decreased by 0.6% 
(aripiprazole patients) and increased by 0.3% (olanzapine patients), risk difference  
0.9%. Among 1000 patients, treatment with aripiprazole versus olanzapine would 
avert 203 metabolic syndrome events, 51 diabetes events, and 9 CHD events at a cost 
of R$1,520.63, R$1.856, and R$4,122.31, per event avoided respectively. The total 
cost difference was R$440,442. Risk differences were driven primarily by signiﬁcant 
weight and lipid changes between agents, favoring aripiprazole. CONCLUSIONS: 
Antipsychotic-related metabolic adverse events and the consequent risk of diabetes 
and CHD can add substantively to health care costs among patients with schizophre-
nia in Brazil. Health care providers should consider these risks in the selection of 
appropriate antipsychotic agents.
PMH5
COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE 
VERSUS QUETIAPINE IN SCHIZOPHRENIC PATIENTS
Elkis H1, Pereira M2, Kayo M1, Duchesne I2, Alandete JC3
1University of São Paulo, São Paulo, Brazil, 2Janssen Cilag, São Paulo, Brazil, 3Janssen-Cilag 
Colombia, Bogota, Colombia
OBJECTIVES: To assess the cost-effectiveness of treatment of schizophrenia with 
Risperidone long acting injectable (RLAI) in comparison with oral Quetiapine using 
an economic model. METHODS: A decision-tree model was built using a treatment 
algorithm simulating the Brazilian Public Health System and applying the rehospital-
ization rates extracted from a 2-year head-to-head study which compared RLAI and 
oral quetiapine. Cost data were extracted from an analysis of direct cost of hospitaliza-
tion in a Brazilian public mental health hospital. As usual in the Public Health System, 
patients considered in this model had previously used Oral Risperidone and were 
elegible to use other second-generation antipsychotics, as well as switch to others. 
RESULTS: In the head-to-head comparison, patients treated with RLAI had a rehos-
pitalization rate of 33.1%, while patients treated with Quetiapine had a rehospitaliza-
tion rate of 16.5% (p  0.0001). In a hypothetical cohort of 1000 patients followed 
for two years, the number of hospital days was 3.3 higher in the Quetiapine group, 
and the number of patients requiring hospitalization in the Quetiapine group was 1.8 
higher, which represent 139 patients without hospitalization in the RLAI group in the 
same period. Mean number of days at hospital was lower with RLAI (32 days) than 
with Quetiapine (64 days). RLAI was the treatment with lower direct cost, generating 
an annual saving of R$1040.00 per patient in the Public System. CONCLUSIONS: 
In comparison with Quetiapine, RLAI is cost saving, due to lower rehospitalization 
rates.
PMH10
ANÁLISE DE CUSTO EFETIVIDADE DOS ANTIPSICÓTICOS  
ATÍPICOS NO TRATAMENTO DA ESQUIZOFRENIA COM BASE NO 
NNT(NÚMERO NECESSÁRIO TRATAR)
Pereira M, Duchesne I
Janssen-Cilag, São Paulo, Brazil
OBJETIVOS: A Medicina Baseada em Evidências é importante por fornecer indica-
dores que avaliam a eﬁcácia de tratamento em perceptiva mais prática, como o número 
necessário tratar (NNT), que representa o número de pacientes que é necessário tratar 
para obter um desfecho favorável, comparado a taxa de sucesso do grupo controle. 
O NNT é útil na tomada de decisão, pois demonstra pelo impacto orçamentário não 
só o “custo de sucesso” (custo efetividade) mas tambem o “custo de desperdício”. Um 
NNT de 7.0 signiﬁca que é necessário tratar 7 pacientes para obteção de um desfecho 
favorável, signiﬁcando que 6 pacientes foram tratados sem sucesso. O Sistema de 
Saúde Público (SUS) do Brasil apresenta atualmente altos custos no tratamento da 
esquizofrenia. Paliperidona é um novo antipsicótico atípico oral de liberação pro-
longada e dose diária única.O objetivo é demonstrar por análise de custo efetividade 
baseada em NNT,o custo para obtenção de sucesso clínico, para antipsicóticos atípicos 
(paliperidona, olanzapina, quetiapina, ziprazidona, aripiprazol). MÉTODOS: Os 
valores de NNT utilizados para olanzapina, ziprasidona, quetiapina e aripiprazol 
foram obtidos de revisões sistemáticas da Cochrane. O NNT da paliperidona foi reti-
rado da bula. Para cálculo dos custos diários de tratamento foi utilizada a Dose Diária 
Deﬁnida (DDD) e preços retirados da revista indexada. RESULTADOS: Os valores 
de NNT encontrados foram: 7.0 olanzapina, 5.0 aripiprazol, 7.0 ziprasidona e 8.0 
quetiapina. Para paliperidona, o NNT obtido foi 3.87. Os custos para obter um 
sucesso clínico foram, R$3,851 (olanzapina), R$ 2,747 (aripiprazol), R$2,423 
(ziprasidona), R$6,115 (quetiapina) e R$2,003 (paliperidona). CONCLUSÕES: 
 Paliperidona demonstrou o melhor NNT e o menor “custo de sucesso clinico” com-
parada aos outros atípicos. Assim, a escolha do tratamento com a paliperidona torna-
se uma opção eﬁciente.
PMH6
COSTO-EFECTIVIDAD DE OCHO MEDICAMENTOS ANTIPSICÓTICOS 
EN COLOMBIA
Alandete J1, Rosselli D2
1Janssen-Cilag Colombia, Bogotá, Colombia, 2Independiente, Bogotá, Colombia
OBJECTIVOS: Evaluar la costo-utilidad de los principales medicamentos antipsicóti-
cos en el contexto colombiano. METODOLOGÍAS: Con un modelo de árbol de 
decisión (horizonte temporal de un año, perspectiva de tercero pagador), se simulan 
ocho medicamentos antipsicóticos: haloperidol y siete atípicos (aripiprazol, clozapina, 
olanzapina, paliperidona, quetiapina, risperidona y ziprasidona). Se utilizaron datos 
de efectividad y adherencia del estudio CATIE, los valores de haloperidol, clozapina 
y paliperidona se obtuvieron de estudios clínicos y panel de expertos locales. Los 
eventos adversos se obtuvieron de estudios clínicos. Los costos directos sanitarios 
corresponden al valor de facturación de prestadores de servicios de salud locales y la 
calidad de vida en QALY se obtuvo del registro de utilidades de Tufts. Tasa de cambio 
US$1  Col$2391. RESULTADOS: El costo de atención en salud anual promedio fue: 
haloperidol US$1724, paliperidona US$2263, risperidona US$2546, clozapina 
US$2963, ziprasidona US$2998, quetiapina US$3500, olanzapina US$3645, y aripip-
razol US$3890. Comparado con haloperidol, la menor razón incremental de costo-
utilidad corresponde a paliperidona (US$25.8K / QALY). En los otros atípicos, ésta 
varía entre US$54K (risperidona) y US$238K (aripiprazol). Estos valores estarían 
magniﬁcados por las pequeñas diferencias en utilidades (entre 0.63 QALY para halo-
peridol y 0.65 QALY para olanzapina y paliperidona). Considerando lo anterior, cal-
culamos el beneﬁcio neto. Con una disponibilidad a pagar de US$25K por QALY, 
haloperidol y paliperidona generarían un beneﬁcio similar (US$14.1K) que es mayor 
al de cualquier otro atípico (entre US$12.7K con olanzapina y US$13.7K con risperi-
dona). CONCLUSIONES: Haloperidol sigue siendo el antipsicótico más costo- 
efectivo en el mercado. En este modelo, que minimiza diferencias en efectividad, el 
único antipsicótico costo-efectivo comparable con haloperidol es la paliperidona. Un 
trabajo posterior incluirá costos indirectos y un seguimiento mayor. Estos resultados 
sugieren que paliperidona sería el medicamento de elección al prescribir un antip-
sicótico atípico oral.
PMH7
HEALTH CARE RESOURCE UTILIZATION IN THE TREATMENT OF 
DEPRESSION IN MEXICO
Rivas R, Zapata L
Guia Mark, Mexico, DF, Mexico
OBJECTIVES: Depression is one of the most frequent mental health ailments. It has 
been estimated that by year 2020, it will be the worldwide second cause for the loss 
of healthy life years and the ﬁrst cause in developed countries. In Mexico, the preva-
lence of major depression is estimated from 7% to 12%. However there is not infor-
mation regarding health care resources use in Mexico for this pathology. This, study’s 
objective is to document the health care resource use for depression treatment in 
Mexico. METHODS: Twenty one mental health specialists from a public health 
institution were asked to answer a questionary. Additionally, modiﬁed Delphi method 
was applied with eight specialist to further analyze some of the topics. A database 
was created from the answers and a statistic analysis was performed. RESULTS: Sixty 
percent of the ambulatory patients of the psiquatric area turn to the specialist due to 
depression and from these 40% due to major depression. Eighteen percent of the 
depression patients require hospitalization and, in average, they stay in the hospital 
25 days. Approximately 39% of the patients with major depression become handi-
capped 3 periods of 14 days during the treatment. The average prescription time for 
the anti-depressive drugs is 11.3 months; however, the specialist reported that the 
prescription time could be from 4 to 27 months. CONCLUSIONS: This study provides 
base line information regarding the use of health care resources use in the treatment 
of depressed patients in Mexico. Further evaluations of the disease burden in the 
country should be performed.
MENTAL HEALTH – Patient-Reported Outcomes Studies
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FACTORES ASOCIADOS AL INCUMPLIMIENTO DE TRATAMIENTOS 
CON ANTIDEPRESIVOS EN SANTIAGO, CHILE
Jirón M1, Escobar L1, Arriagada L2, Orellana S1, Castro A2, Sandoval R1, Salazar N1
1Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile, 
2Hospital Clínico de la Universidad de Chile, Santiago, Chile
OBJECTIVOS: Identiﬁcar los factores asociados al incumplimiento de tratamientos 
con antidepresivos (AD) en Santiago, Chile. METODOLOGÍAS: Mediante un estudio 
transversal se entrevistó en hogares a una muestra representativa y probabilística de 
1000 personas q 15 años en Santiago, Chile. Los datos se analizaron a través de 
estadística descriptiva y regresiones logísticas con STATA 8.0. RESULTADOS: De los 
171(17.1%)sujetos que declararon haber consumido alguna vez en su vida AD, el 
52.4% declaró ser incumplidor para dosis, tiempo recomendado de uso y/o ambas 
(33.2% para dosis y 38.3% para tiempo de uso). Al estudiar el incumplimiento al 
tiempo recomendado de uso, se observaron diferencias signiﬁcativas en Grupo Socio-
económico (GSE) bajo que presentó 5.3 veces más riesgo de incumplimiento que GSE 
alto (OR  5.3; IC95% 1.51–18.40; p  0.009). La condición de mujer con GSE 
medio-alto y bajo presentó más riesgo de incumplimiento que mujer de GSE alto (OR 
 3.95; IC95% 1.29–12.15; p  0.016) y (OR  4.3; IC95% 1.11–16.52; p  0.035), 
respectivamente. Además, al estudiar el incumplimiento a la dosis prescrita se observó 
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que GSE medio-bajo presentó 3 veces más riesgo de incumplimiento que GSE alto 
(OR  3.26; IC95% 1.04–10.28; p  0.043). Los sujetos con escolaridad 9 años 
presentaron 2.5 veces más riesgo de incumplimiento que aquellos con escolaridad 12 
años (OR 2.5; IC95% 1.01–6.02; p  0.047). La condición de hombre del GSE medio-
bajo presenta 11 veces más riesgo de incumplimiento que GSE alto (OR 11.0; IC95% 
1.11–109.39; p  0.041). Al estudiar el incumplimiento a la dosis prescrita, al tiempo 
de uso o ambas, se observó que GSE medio-bajo presentó 3.6 veces más riesgo de 
incumplimiento que GSE alto (IC95% 1.19–10.71; p  0.023). CONCLUSIONES: 
Los ingresos económicos y el nivel de escolaridad son factores determinantes en el 
cumplimiento de los tratamientos con antidepresivos en Santiago, Chile. Por lo tanto, 
las estrategias sanitarias deberían estar dirigidas a disminuir las inequidades produci-
das por estas condiciones.
PMH9
VALIDATION OF PEER RELATIONS SCALE FOR ADOLESCENTS 
TREATED FOR SUBSTANCE USE DISORDER: AN APPLICATION OF 
RASCH MODELING
Ciesla J
Northern Illinois University, DeKalb, IL, USA
OBJECTIVES: A signiﬁcant and growing body of literature indicates that positive 
supportive peer relations are protective of relapse for adolescents treated for psychoac-
tive substance use disorder (PSUD). Unfortunately, no standard measure of peer rela-
tions exists. The objective of this research is to use Rasch modeling as an application 
of item response theory (IRT) to validate a 14-item peer relations scale for use in 
outcomes assessments in this treatment population. METHODS: Subjects are 509 
adolescents discharged from primary substance abuse treatment from 2004–2007. The 
data is from an outcome assessment conducted between 6 and 12 months post dis-
charge via a 234-item questionnaire that included the 14-item peer relations scale. The 
scale has questions that assess the degree to which the adolescent’s peers conform to 
norms of positive behavior and the degree to which the peers are supportive of absti-
nence and recovery. Response rate was 62%. RESULTS: The person reliability is 0.76 
and the Cronbach’s alpha person raw score reliability is 0.93 both indicating the scale 
is a strong metric. The item reliability of 0.99 is high and shows that the model is 
reliable. The real separation (8.49) meaning items are placed reliably on the Rasch 
“ruler” with about eight levels of importance identiﬁed. The mean-square (MNSQ) 
statistic of the inﬁt and outﬁt values were between 0.5 and 1.5 for all of the items 
indicating a low level of randomness and thus unidimensionality of the scale. Visual 
inspection of a Wright Item Map shows the hierarchical structure of the scale with a 
moderate degree of inter-item spread. Similarly, the standardized t-tests (Z-STD) 
shown on a pathway bubble chart indicate a moderate degree of item overlap. 
 CONCLUSIONS: The Rasch IRT analysis shows the peer relations scale is a reliable 
unidimensional metric of an important treatment outcome for adolescents treated for 
PSUD.
MUSCULAR-SKELETAL DISORDERS – Cost Studies
PMS1
BUDGET IMPACT ANALYSIS OF ZOLEDRONIC ACID IN POST 
MENOPAUSAL OSTEOPOROSIS BY BRAZILIAN PUBLIC HEALTH  
CARE SYSTEM
Suzuki C1, Navarro J2, Pepe C3
1Novartis Biociências S/A, São Paulo, Brazil, 2Novartis Farmacêutica S.A, São Paulo, Brazil, 
3MedInsight Consulting, Rio de Janeiro, Brazil
OBJECTIVES: To determine the budget impact of incorporating zoledronic acid to 
treat post-menopausal osteoporosis in Brazilian public reimbursement system. 
METHODS: This study considered only postmenopausal women with osteoporotic 
hip fracture above the age of 65. According to DATASUS (public health care system’s 
database), in 2007 there were 11,666 women with these characteristics. The mortality 
rate considered for this population was higher than for those of general population. 
It was applied a relative risk found on literature review for post-fracture years on 
IBGE’s (Brazilian Institute of Geography and Statistic) mortality rate by other causes. 
Only direct medical costs were considered. Based on DATASUS, the follow-up exams 
costs were equivalent to US$37.37 (conversion rate in March 16th  R$2.27/USD 
1.00) per year per patient. The average cost of procedure to treat the fracture was 
extracted from Tabwin (public health care system’s database). The annual costs with 
zoledronic acid and sodium alendronate were US$341.99 and US$12.68, respectively. 
It was presumed 5% per year as zoledronic acid market share in this population and 
the remaining patients of each year would continue the treatment with alendronate. 
RESULTS: The annual impact estimated for 3 consecutive years is US$1.6 million for 
National public health care system. CONCLUSIONS: If only post-menopausal women 
over 65 years old with osteoporotic hip fracture were eligible to zoledronic acid treat-
ment, and presuming that only 5% of this patients per year would take this medica-
tion, an incremental expense of approximately US$1.6 million per year was estimated 
in this analysis. It is expected that this annual increase does not continue for many 
years, once the population eligible to treatment is elderly.
PMS2
ANÁLISE DE CUSTOS DE RITUXIMABE VERSUS INFLIXIMABE, 
ADALIMUMABE, ETANERCEPTE E ABATACEPTE PARA TRATAMENTO 
DA ARTRITE REUMATÓIDE SOB A PERSPECTIVA DE UM PAGADOR 
PRIVADO NO BRASIL
Santos EA, Saggia MG
Roche Brazil, São Paulo, SP, Brazil
OBJETIVOS: Estimar o custo médio anual por paciente do tratamento das terapias 
que podem ser utilizadas na falha de anti-TNF sob a perspectiva de um pagador 
privado no Brasil. MÉTODOS: Como até o momento não foram identiﬁcados estudos 
clínicos que comparassem diretamente as drogas utilizadas na falha de anti-TNF 
assumiu-se que as terapias têm os mesmos desfechos clínicos, em linha com a metodo-
logia utilizada pela autoridade australiana de avaliação de tecnologias (PBAC, 2007). 
O uso de recursos médicos referentes a biológicos, metotrexato, administração endo-
venosa e exames de triagem e rotina, foram levantados com reumatologistas. A dose 
considerada para inﬂiximabe foi de 300 mg, conforme observado nos convênios 
médicos. Então se procedeu ao micro-custeio dos recursos utilizados. As fontes para 
os custos foram: revista Kairos margo 2009 para medicamentos, o artigo de Schein-
berg et al. (2005) para custo de administração e CBHPM para exames. O horizonte 
de tempo da análise é de cinco anos. A taxa de desconto utilizada foi de 5% conforme 
diretrizes brasileiras de avaliação de tecnologias em saúde (Vianna et al., 2007). 
Análises de sensibilidade uni- e bi-variadas foram conduzidas. RESULTADOS: No 
cenário base, o custo médio anual de rituximabe foi de R$ 47,515 por paciente. Para 
as outras drogas os custos médios anuais por paciente foram: R$ 86,918 (inﬂiximabe), 
R$ 93,098 (adalimumabe), R$ 92,778 (etanercepte) e R$ 75,244 (abatacepte). A 
economia por paciente pode variar de 37% a 49% quando comparamos rituximabe 
com abatacepete e adalimumabe, respectivamente. Como os custos de aquisição das 
drogas representam pelo menos 94% dos custos totais, os resultados foram sensíveis 
à posologia dos biológicos e ao custo de aquisição de drogas. CONCLUSÕES: Os 
achados sugerem que a terapia com rituximabe, no tratamento da falha de anti-TNF 
pode trazer economia de recursos sob a perspectiva do pagador privado no Brasil.
PMS4
COSTO-EFECTIVIDAD DEL USO DE ETANERCEPT VS LOS 
ANTICUERPOS MONOCLONALES ANTI-TNF EN PACIENTES CON 
ARTRITIS REUMATOIDE EN COSTA RICA
Aguirre A1, García E1, Bierschwale H1, Prado M2
1Wyeth México, Naucalpan, Mexico, 2Wyeth Pharmaceuticals Central America, San José, 
Costa Rica
OBJECTIVOS: Determinar la razón de costo-efectividad incremental (RCEI) de etan-
ercept versus los anticuerpos monoclonales anti-TNF en el tratamiento de pacientes 
con AR tomando como base una perspectiva institucional en Costa Rica. 
 METODOLOGÍAS: Se desarrolló un modelo de análisis de decisión para comparar 
la razón de costo-efectividad de etanercept (25 mg dos veces por semana) versus 
adalimumab (40 mg cada dos semanas) e inﬂiximab (3 mg/Kg semana 0, 2, 6 y después 
cada 8 semanas) en pacientes bajo tratamiento de AR con una respuesta inadecuada 
a los fármacos modiﬁcadores de la enfermedad (FARMEs) comúnmente utilizados. 
Tomando como base el precio unitario de cada biológico, se estimó el costo anual de 
tratamiento con cada alternativa. Considerando las tasas de respuesta ACR (American 
College of Rheumatology, Colegio Americano de Reumatología) 50 reportadas en la 
literatura, se estimó la razón de costo-efectividad incremental. RESULTADOS: El 
costo anual de tratamiento con etanercept, adalimumab e inﬂiximab por paciente fue 
de USD$15,184, USD$14,872 y USD$15,336 respectivamente. Las tasas de respuesta 
ACR50 de etanercept, adalimumab e inﬂiximab publicadas en la literatura cientíﬁca 
son 69%, 41% y 21% respectivamente. La RCEI por paciente adicional que alcanza 
una respuesta ACR50 con etanercept en comparación con adalimumab fue de 
USD$1114 y etanercept resultó una estrategia dominante frente a inﬂiximab. 
 CONCLUSIONES: De acuerdo a los resultados, el uso de etanercept en pacientes con 
AR es una alternativa costo-efectiva en comparación con adalimumab al tomar como 
umbral de costo-efectividad el PIB per cápita sugerido por la Organización Mundial 
de la Salud, y costo-ahorradora al comparar etanercept con inﬂiximab. Si se incre-
mentara el uso de etanercept una mayor cantidad de pacientes tendrían acceso al 
tratamiento con terapias biológicas y la Caja de Seguridad Social podría contener 
costos en el tratamiento de la AR en Costa Rica.
PMS5
COST-EFFECTIVENESS OF THE USE OF ETANERCEPT VS ANTI-TNF 
MONOCLONAL ANTIBODIES IN PATIENTS WITH RHEUMATOID 
ARTHRITIS IN MEXICO
Aguirre A1, García E1, Bierschwale H2, Arce CA3
1Wyeth Mexico, Naucalpan, Mexico, 2Wyeth Mexico, Naucalpan, Mexico, Mexico, 3PEMEX 
Picacho Hospital, Mexico City, Mexico
OBJECTIVES: To determine the incremental cost-effectiveness ratio (ICER) of etan-
ercept (a fusion protein) versus other two anti-TNF-á monoclonal antibodies used in 
the treatment of RA, based on a payer perspective. METHODS: A decision analytic 
model was developed to compare the cost-effectiveness of etanercept (25mg twice-
weekly) versus adalimumab (40mg every other week) and inﬂiximab (3mg/Kg in the 
weeks 0, 2, 6 and then every 8 weeks) in RA patients with an inadequate response to 
DMARD’s. To build the model, the price per unit paid by the government Hospitals 
was considered, taking into account the annual total therapy cost. Results on efﬁcacy 
measures from published clinical trials considering an ACR 70 criteria (change from 
the basal in 70% of the ACR parameters) was used in the estimation of the incremental 
